Bellevue Life Sciences Ac... (BLAC)
Bellevue Life Sciences Acquisition Statistics
Share Statistics
Bellevue Life Sciences Acquisition has - shares outstanding. The number of shares has increased by -58.74% in one year.
| Shares Outstanding | - |
| Shares Change (YoY) | -58.74% |
| Shares Change (QoQ) | -42.6% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 2.31M |
| Failed to Deliver (FTD) Shares | 165.33K |
| FTD / Avg. Volume | 1.08K% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 146.22 and the forward PE ratio is null. Bellevue Life Sciences Acquisition's PEG ratio is -0.08.
| PE Ratio | 146.22 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.82 |
| P/FCF Ratio | -72.11 |
| PEG Ratio | -0.08 |
Enterprise Valuation
Bellevue Life Sciences Acquisition has an Enterprise Value (EV) of 59.03M.
| EV / Sales | 0 |
| EV / EBITDA | 62.49 |
| EV / EBIT | -72.09 |
| EV / FCF | -72.09 |
Financial Position
The company has a current ratio of 0.01, with a Debt / Equity ratio of 0.
| Current Ratio | 0.01 |
| Quick Ratio | 0.01 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 1.24% and Return on Invested Capital is -2.26%.
| Return on Equity | 1.24% |
| Return on Assets | 1.1% |
| Return on Invested Capital | -2.26% |
| Revenue Per Employee | $- |
| Profits Per Employee | $- |
| Employee Count | undefined |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 540.81K |
| Effective Tax Rate | 57.25% |
Stock Price Statistics
The stock price has increased by -71.87% in the last 52 weeks. The beta is 0.53, so Bellevue Life Sciences Acquisition's price volatility has been higher than the market average.
| Beta | 0.53 |
| 52-Week Price Change | -71.87% |
| 50-Day Moving Average | 10.9 |
| 200-Day Moving Average | 10.89 |
| Relative Strength Index (RSI) | 13 |
| Average Volume (20 Days) | 15.26K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -1.83M |
| Net Income | 403.78K |
| EBITDA | 944.59K |
| EBIT | 944.59K |
| Earnings Per Share (EPS) | 0.07 |
Balance Sheet
The company has 15.42K in cash and 0 in debt, giving a net cash position of 15.42K.
| Cash & Cash Equivalents | 15.42K |
| Total Debt | 0 |
| Net Cash | 15.42K |
| Retained Earnings | -3.91M |
| Total Assets | 20.93M |
| Working Capital | -3.9M |
Cash Flow
In the last 12 months, operating cash flow was -818.77K and capital expenditures -4, giving a free cash flow of -818.77K.
| Operating Cash Flow | -818.77K |
| Capital Expenditures | -4 |
| Free Cash Flow | -818.77K |
| FCF Per Share | -0.15 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BLAC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 0.68% |
| FCF Yield | -1.39% |
Analyst Forecast
Currently there are no analyst rating for BLAC.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -0.28 |
| Piotroski F-Score | 1 |